Latest Breaking News On - Debbie etchison - Page 2 : comparemela.com
Scynexis (SCYX) Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ (riluzole) is Now Available in the U S for the Treatment of ALS
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MTPA Announces PANTHERx® Selected as Exclusive Provider of U S Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
JERSEY CITY, N.J., May 12, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA
® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS). The analysis will be presented during the 2021 European Network to Cure ALS (ENCALS) Meeting, being held virtually May 12-14. Initial insights shared with the scientific community during ENCALS are a part of our wide-ranging efforts to compile real-world data that can be used to learn as much as possible about the clinical experience of RADICAVA, said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. We utilized a rigorous statistical methodology to comprehensively assess more than two years of administrative claims data for our therapy. Analysis is still ongoing, and we look forward to sharing more details about the methodology
Share this article
Share this article
JERSEY CITY, N.J., April 20, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of the timing of disease progression milestones among commercially insured amyotrophic lateral sclerosis (ALS) patients treated with intravenous (IV) RADICAVA
® (edaravone). The findings are being presented during the 2021 Virtual American Academy of Neurology (AAN) Annual Meeting, held April 17-22. We are pleased to share these data, which may provide information to the ALS community by observing the time to real-world milestones associated with ALS progression, said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. The results from this new analysis of real-world data gives clinicians more information that may be useful in evaluating treatment for their patients.